News

February 23, 2026

GlobeNewswire

Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director

December 5, 2025

Watch Neutrolis’ late-breaking presentation from ACR 2025 in Chicago, delivered by Toby Fox (Co-founder, CSO)

October 29, 2025

Endpoints News

Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest

October 29, 2025

GlobeNewswire

Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated Neutrophil Extracellular Trap (NET) Clearance as a Therapeutic Approach in Autoimmunity at American College of Rheumatology Convergence 2025

October 13, 2025

GlobeNewswire

Neutrolis Announces Late-Breaking Oral Presentation of Clinical Results at American College of Rheumatology Convergence 2025

March 10, 2025

Citeline

Biotech Aims For NET Gains By Targeting Neutrophil Extracellular Traps

December 23, 2024

GlobeNewswire

Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs

December 18, 2024

GlobeNewswire

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases

News and Press Releases

Press Releases

Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director

Watch Neutrolis’ late-breaking presentation from ACR 2025 in Chicago, delivered by Toby Fox (Co-founder, CSO)

Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest

Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated Neutrophil Extracellular Trap (NET) Clearance as a Therapeutic Approach in Autoimmunity at American College of Rheumatology Convergence 2025

Neutrolis Announces Late-Breaking Oral Presentation of Clinical Results at American College of Rheumatology Convergence 2025

Biotech Aims For NET Gains By Targeting Neutrophil Extracellular Traps

Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases

In the News

Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest

Biotech Aims For NET Gains By Targeting Neutrophil Extracellular Traps

Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs read more...

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases read more...

Watch Neutrolis’ late-breaking presentation from ACR 2025 in Chicago, delivered by Toby Fox (Co-founder, CSO).

For media inqueries contact
ir@neutrolis.com

News and Press Releases

Press Releases

Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director

Watch Neutrolis’ late-breaking presentation from ACR 2025 in Chicago, delivered by Toby Fox (Co-founder, CSO)

Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest

Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated Neutrophil Extracellular Trap (NET) Clearance as a Therapeutic Approach in Autoimmunity at American College of Rheumatology Convergence 2025

Neutrolis Announces Late-Breaking Oral Presentation of Clinical Results at American College of Rheumatology Convergence 2025

Biotech Aims For NET Gains By Targeting Neutrophil Extracellular Traps

Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases

In the News

Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest

Biotech Aims For NET Gains By Targeting Neutrophil Extracellular Traps

Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs read more...

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases read more...

Watch Neutrolis’ late-breaking presentation from ACR 2025 in Chicago, delivered by Toby Fox (Co-founder, CSO).

For media inqueries contactir@neutrolis.com

For media inqueries contact
ir@neutrolis.com